Kornimate/medical-research-clean huggingface dataset:
transauricular vagus nerve stimulation improves postoperative sleep disorders in elderly patients.

Conditions: Vagus Nerve Stimulation

Summary: postoperative sleep disorder is one of the common complications after general anesthesia. compared to patients of various ages, elderly patients have a much higher incidence of postoperative sleep disturbance. postoperative sleep disorders can have many adverse effects, including cognitive impairment, altered pain perception, and emotional disorders, which are not conducive to the long-term prognosis of elderly patients. enhancing postoperative sleep quality in older patients has become a significant public health concern in the current day due to its direct relationship to both maximizing surgical outcomes and enhancing physical health. this study intends to conduct a prospective, randomized controlled, triple-blind clinical trial on use of transauricular vagal nerve stimulation to improve sleep disorders in elderly patients after general anesthesia surgery, aiming to investigate the efficacy of transauricular vagal nerve stimulation in postoperative sleep disorders in elderly patients.


Eligibility criteria:
inclusion criteria: * patients undergoing non-craniocerebral surgery under elective general anesthesia * age ≥65 years old * american society of aneshesiologists grade i to iii * sign informed consent exclusion criteria: * patients who are expected to retain tracheal intubation after surgery * disturbance of consciousness, mental disorder, inability to cooperate * expected survival \< 3 months * the estimated operation time is \< 2 hours * the expected postoperative hospital stay is \< 5 days
b-line by lung us in patients with acute decompensated heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate that b-line detected by lung ultrasound before extubation in patients with acute decompensated heart failure can predict future risk of reintubation and clinical outcomes during admission in korea.


Eligibility criteria:
inclusion criteria: * mechanical ventilation due to acute heart failure exclusion criteria: * none
video laryngoscope vs. video stylet during general anesthesia with obesity patient

Conditions: Intubation; Difficult or Failed; Obesity

Summary: obesity patients are more common in recent years. they have potential difficult airway. two different video devices are popular used in taiwan, video larygoscope and video stylet. we compared video larygoscope (mcgrath mac) and video stylet (trachway) during elective surgery require tracheal intubation with obesity patients. the control group is traditional laryngoscope. 325 patients would be enrolled, above 100 patient each group.


Eligibility criteria:
inclusion criteria: * elective surgery needs intubation * asa i to iii * bmi\>30kg/m2 exclusion criteria: * head and neck cancer * skull, neck fracture * tracheal trauma * npo\< 8hr * lung disease with hypoxemia * mental disorders * patient wouldn't be extubated after operation immediately * contraindicated to muscle relaxant

Keywords: obesity intubation
ultrasound radiomics for predicting breast cancer and axillary lymph node metastasis

Conditions: Breast Cancer; Axillary Lymph Node Metastasis

Summary: the project is proposed based on multimodal ultrasonic imaging omics building used for accurate prediction of the breast cancer and axillary lymph node metastasis load artificial intelligence forecasting model, this method can dig the hidden features of ultrasonic image is not visible to the naked eye, make up the subjectivity in the process of clinical doctors in diagnosis and treatment, provide accurate, objective basis for clinical decision making.


Eligibility criteria:
inclusion criteria: * patients who have not received breast puncture biopsy or neoadjuvant chemotherapy, etc. prior to ultrasonography; * patients who are not allergic to the ultrasound contrast agent (sonovue) and have signed an informed consent form for ultrasonography * patients with breast tumors who have undergone surgical treatment at our hospital and have complete case histories. exclusion criteria: * patients with incomplete case data; * cases with large breast masses that do not completely show the region of interest (roi); * patients who have undergone breast aspiration biopsy or other treatments such as neoadjuvant chemotherapy or endocrine therapy before ultrasound examination.

Keywords: breast cancer multi-modal ultrasound radiomics
pembrolizumab combined with double platinum based chemotherapy for potentially resectable nsclc

Conditions: Non Small Cell Lung Cancer

Summary: this study aims to explore the efficacy and safety of pembrolizumab combined with double platinum-based chemotherapy for potentially resectable non-driver gene mutation non-small cell lung cancer

inclusion criteria: diagnosed with non-small cell lung cancer egfr and alk and ros1 negative treatment naive potentially resectable identified by mdt

Eligibility criteria:
inclusion criteria: * ≥18，advanced non-squamous non-small cell lung cancer confirmed by histopathology * potentially resectable nsclc * treatment plan is crizotinb or standard chemotherapy exclusion criteria: * patients with contraindication of chemotherapy * pregnant or breast feeding women
feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the clinical research center (crc) setting.

this study is a non-randomized, uncontrolled feasibility study that looks to enroll people with type 1 diabetes who are currently using an insulin pump. during the subject's participation, the study staff will closely monitor the study subject in a clinical research center environment for approximately 24 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results. total subject participation approximately 1 week for screening to completion. this includes approximately 24 hours usage of the investigation device in the clinical research center under close medical supervision.

Eligibility criteria:
summary of key inclusion/exclusion criteria: inclusion criteria: * age 21-65 years * type 1 diabetes mellitus for at least one year * using an insulin infusion pump for at least the past 6 months exclusion criteria: * pregnancy * history of diabetic ketoacidosis (dka) in the past six months * history of severe hypoglycemia (seizure, unconsciousness) in the past 6 months other inclusion/exclusion criteria apply. please contact clinical study site for complete details.

Keywords: type 1 diabetes mellitus artificial pancreas
case collection study in the evaluation of doubling time rates in non-suspicious breast masses using qt ultrasound technology

Conditions: Breast Fibroadenoma

Summary: this is a prospective case collection study to collect cases for subsequent statistical studies and future reader studies.


Eligibility criteria:
inclusion criteria: 1. female 2. age 18 or older 3. willing to receive qt ultrasound breast scans 4. willing to undergo an ultrasound-guided needle breast biopsy if performed after enrollment in the study 5. willing and able to provide informed consent prior to any research-related procedure(s) 6. have an identified solid non-suspicious breast mass exclusion criteria: 1. pregnancy 2. currently breastfeeding 3. magnetic material in the chest which in the judgement of the principal investigator would interfere or be impacted by the magnets utilized with the study device. 4. not willing to provide information for primary care physician 5. history of breast cancer 6. history of treated or untreated cancer of a non-breast origin which in the judgment of the principal investigator would be a concern for metastatic disease to the breast 7. physical inability to tolerate the qt scan, i.e. inability to lie prone and still for up to 30 minutes at a time 8. open wounds, sores or skin rash present on the breast(s) or nipple discharge from the scanned breast(s) 9. breasts too large for scanner, i.e. bra size larger than ddd or inability to successfully "fit" breast after the subject is placed on scanner 10. body weight greater than 400 lbs. (180 kg) 11. concurrent disease or condition which in the judgment of the principal investigator disqualifies the subject from participating in the study
future of beta cells in adults with genetic abnormality behind neonatal diabetes

Conditions: Diabetes

Summary: the main objective of this study is to evaluate beta cells in patients with a neonotal diabetes linked to a genetic abnormality metabolic caracteristics will described using a transversal cohort study.


Eligibility criteria:
inclusion criteria: * age : 18 à 65 year * diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline or patient with a relative having neonatal diabetis exclusion criteria: diabète induit (médicaments - ex corticoïdes) ou syndromique * infection * cancer * pegnancy
personalized antisense oligonucleotide for a single participant with chchd10 als

Conditions: Amyotrophic Lateral Sclerosis

Summary: this research project entails delivery of a personalized antisense oligonucleotide (aso) drug designed for a single participant with amyotrophic lateral sclerosis (als) due to a pathogenic variant in chchd10


Eligibility criteria:
inclusion criteria: * informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s). * ability to travel to the study stie and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records. * genetically confirmed neurological disorder. exclusion criteria: * participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures. * use of an investigational medication within less than 5 half-lives of the drug at enrollment
topical proparacaine eye drops to improve the experience of patients undergoing intravitreal injections

Conditions: Age-related Macular Degeneration; Diabetic Macular Edema; Injection Site; Injection Site Infection; Pain, Postoperative

Summary: the specific aims of this study are to compare patient experience with and without a proparacaine drop after povidone iodine.

to ensure the extra drop does not interfere with antisepsis, conjunctival cultures will be obtained from patients undergoing intravitreal injection before and after the application of the extra eye drop. patients will be randomized to undergo additional topical analgesia during intravitreal injection vs. the standard amount of topical analgesia. cultures of the eyelid/conjunctiva will be taken to ensure that the additional topical analgesia does not interfere with antisepsis.

Eligibility criteria:
inclusion criteria: * patients undergoing intravitreal injection who do not have active eye infections * greater than 18 years of age exclusion criteria: * patients younger than 18 years of age * patients with active eye infections
is theophylline more effective than sumatriptan in the treatment of post-dural puncture headache

Conditions: Post-Dural Puncture Headache

Summary: objectives: to compare the safety and efficacy of oral theophylline versus oral sumatriptan in the treatment of post-dural puncture headache (pdph). background: pdph is the most frequent complication of procedures associated with dural puncture for spinal anesthesia or following accidental dural puncture during epidural anesthesia. since invasive treatments have known complications, pharmacologic management may be preferable. patients and methods: this was a prospective, randomized, double-blind, phase four clinical trial; carried out on 60 patients presented with pdph at our hospital. patients were randomly allocated into two equal groups (30 patients each); group t, received oral theophylline, and group s, received oral sumatriptan.


Eligibility criteria:
inclusion criteria: * patients with nprs score of ≥ 5 * american society of anesthesiologists (asa) physical status ≤ ii * age from 21 to 50 years exclusion criteria: * patients with nprs score \< 5 * asa physical status \> ii * age \ 50 years * pregnant women * history of; chronic headache, cluster headache, migraine * history of; convulsions, cerebrovascular accident, previous neurological diseases * history of peripheral vascular disease (ischemic colitis) * signs of meningismus * dysrhythmia * hypertension * ischemic heart disease * hyperthyroidism * liver or renal impairment * use of selective serotonin reuptake inhibitors (ssris) * use of ergotamine derivatives in the past 24 hours * use of monoamine oxidase inhibitors (maois) in the last two weeks * use of any kind of opiates * allergy to the study medications * any contraindication of oral intake

Keywords: post-dural puncture headache spinal anesthesia sumatriptan theophylline
three dimensional navigation intracardiac guidance kit for atrial septal puncture

Conditions: Atrial Fibrillation

Summary: this study aims to evaluate the safety and efficacy of a three-dimensional navigation intracardiac guidance kit to perform atrial septal puncture in patients requiring catheter ablation, which will be compared with procedures using traditional kit for atrial septal puncture.

atrial septal puncture has become a key technique in cardiac interventional procedures. traditional septal punctures are routinely perfomed under two-dimensioanl guidance, whic are likely to be not acurate sometimes. this study is aimed to study the safety and efficacy of a novel designed three-dimensional navigation intracardiac guidance kit for atrial septal puncture in patients with atrial fibrillation requiring catheter ablation and to explore the possibility of transseptal without fluoroscopy using the three-dimensional positioning intracardiac guidance.

Eligibility criteria:
inclusion criteria: 1. diagnosed with atrial fibrillation. 2. requiring catheter ablation therapy. 3. voluntarily sign the informed consent. exclusion criteria: 1. previous atrial septal puncture. 2. blood clots in the left atrium or left atrial appendage 3. left atrial mucinous tumor. 4. atrial septal defect, including previous surgical correction or interventional occlusion. 5. acute or severe systemic infection. 6. cardiac function (nyha classification) ⅲ-ⅳ. 7. contraindications to anticoagulation. 8. left ventricular ejection fraction \<35%. 9. patients with untreated or uncontrolled hyperthyroidism or hypothyroidism. 10. patients with malignancy with expected survival of less than 1 year. 11. myocardial infarction or any cardiac intervention or open procedure within the last 3 months 12. stroke and other cerebrovascular disease or thromboembolic disease within the last 3 months. 13. participated in clinical trials of other drugs or devices in the past 3 months. 14. any other condition that the investigator deems inappropriate for participation in this trial.

Keywords: atrial septal puncture three dimensional fluroscopy catheter ablation
mindfulness-based intervention in breast cancer patients undergoing chemotherapy

Conditions: Breast Cancer

Summary: there is evidence that mindfulness-based interventions (mbis) such as meditation, mindfulness-based stress reduction (mbsr) and yoga might improve quality of life (qol) and reduce stress in breast cancer survivors. these interventions are becoming increasingly popular in cancer survivors. however, little is known about the feasibility and effect of mbis administered during the interval of time of chemotherapy, on qol and stress. the investigators are planning a mbi intervention study developed specifically for breast cancer survivors receiving chemotherapy (usually 4-5 months) at the investigators institution, for at least 8 sessions combined with at least 8 weeks of home-practice, in 25 women receiving chemotherapy for breast cancer.


Eligibility criteria:
inclusion criteria: * women 20-75 years old * diagnosed with breast cancer * scheduled to begin chemotherapy at mayo clinic rochester exclusion criteria * pregnant * practicing mindfulness
patient satisfaction & abutment teeth health in maxillectomy patients

Conditions: Maxillary Diseases

Summary: randomized controlled trial in maxillectomy patients with two types of obturators with different manufacturing techniques

randomized controlled trial measuring patient satisfaction and abutment teeth health in maxillectomy patients rehabilitated with laser polished cad cam obturators versus conventionally constructed obturators

Eligibility criteria:
inclusion criteria * patients with hemi maxillectomy * sufficient number of natural teeth not less than 5 teeth * age between 30 and 60 years * intact soft palate exclusion criteria * cognitive impairment * heavy smokers * patients exposed to radiotherapy
retinal investigation using optos oct device

Conditions: AMD - Age-Related Macular Degeneration; Retinitis Pigmentosa (RP); Diabetic Retinopathy; Control Patients

Summary: retinal investigation using oct with control and diseased eyes


Eligibility criteria:
inclusion criteria: 1. male or female participants 18 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed. 2. participants who understand the study and patient information sheet and can follow the instructions. 3. participants who agree to participate in the study. 4. control group where no retinal abnormalities were detected as part of the standard basic ophthalmic examination. 5. participants with retinal disease in at least one eye including: early dry age-related macular degeneration, late stage dry age-related macular degeneration specifically geographic atrophy, wet age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy and other macular atrophic diseases exclusion criteria: 1. inability to understand written and verbal english sufficiently to comprehend the study and provide informed consent 2. ophthalmic disease other than condition under investigation. 3. participants unable to tolerate ophthalmic imaging. 4. cataract (unless deemed mild in the opinion of the investigator) 5. participants with significant ocular media not sufficiently clear to obtain acceptable oct images. 6. diabetes (unless part of the diabetic eye disease group) 7. binocular visual acuity worse than 6/18 8. strabismus (squint) 9. age related macular degeneration groups: polypoidal choroidal vasculopathy 10. participants with photo sensitivity epilepsy, experience of seizures, or sensitivity to flickering light (based on self-report) 11. pregnant
effect of guanfacine extended-release on attention deficit hyperactivity disorder (adhd)-associated insomnia

Conditions: Attention-Deficit/Hyperactivity Disorder; Attention Deficit Disorder; Insomnia; Sleep Disorders

Summary: this study seeks to determine, using special sleep tests (polysomnography and actigraphy) if guanfacine extended release is able to improve nighttime sleep in children with adhd - associated insomnia while improving daytime adhd symptoms. male and female children with diagnosed or suspected adhd with sleep problems (difficulty falling asleep, difficulty staying asleep, or less than expected hours of sleep) will be recruited. after obtaining informed consent and assent (when appropriate) and after discontinuation of excluded medications, children will have evaluations of his or her sleep and evaluations confirming the adhd diagnosis. children who successfully pass screening will be enrolled into the double-blind, placebo-controlled, randomized investigation with 50% of participants receiving guanfacine extended release and 50% of participants receiving matching placebo. using a flexible-dose optimization design based on adhd symptom improvement and medication tolerability, the dose will be adjusted between 1 to 4 mg over the course of four weeks. at the end of medication adjustment (week 4 or 5), adhd questionnaires, sleep questionnaires, and sleep tests will be repeated and analyzed. the medication will be weaned over the course of the following 3-10 days.


Eligibility criteria:
inclusion criteria: 1. subject must be male or female, aged 6 - 12 years with adhd. 2. subject must (a) be taking methylphenidate, amphetamine, or atomoxetine for treatment of adhd with parent or subject concerns of inadequate efficacy or intolerable side effects, or (b) free of any other medication used to treat adhd for at least 30 days at the time of the initial sleep study. 3. subject must have repeated difficulty with sleep initiation or persistence despite attempts at adequate sleep hygiene. 4. subject must be able to swallow tablets. exclusion criteria: 1. subject or parent/lar is unable or unwilling to discontinue present medications used to treat adhd. 2. subject has a body mass index \< 5th percentile for age, using the centers for disease control standards reported in 2000. 3. subject has a body weight \> 176 pounds. 4. subject has a diagnosis of autism or autism spectrum disorder. 5. subject has other serious psychiatric diagnoses. 6. subject has a medical condition that may require treatment with an unapproved medication, that may cause a safety concern, or that may confound outcome results 7. subject has an excessive caffeine intake (greater than 2.5 mg/kg/d). 8. subject has a prior problem with clonidine or guanfacine.

Keywords: adhd add sleep disturbance
multimechanistic treatment over time of migraine symptoms (movement)

Conditions: Migraine

Summary: movement (multimechanistic treatment over time of migraine symptoms) is a phase 3 study to evaluate the long-term safety of chronic intermittent use of axs-07 and to assess the effect of axs-07 on migraine symptoms following repeated treatment of migraine attacks.

this study is a phase 3, multicenter, open-label, trial to evaluate the long-term safety and efficacy of intermittent chronic dosing with axs-07 in subjects with migraine attacks. eligible subjects will take axs-07 following the onset of a migraine. subjects will be treated for up to 12 months.

Eligibility criteria:
inclusion criteria: * has participated in a prior study with axs-07 for the treatment of migraine exclusion criteria: * has previously received any investigational drug or device or investigational therapy within 30 days before screening, other than axs-07 * pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

Keywords: axsome axs-07 moseic™ meloxicam rizatriptan
short term warfarin therapy for radiofrequency catheter ablation of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: we hypothesized that in patients with low chads-vasc score (2 or \< 2), there is no difference in thromboembolic or bleeding events between patients with short term warfarin therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8 weeks after procedure).


Eligibility criteria:
inclusion criteria: * patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter ablation * patients with chads-vasc score 2 or less than 2 exclusion criteria: * patients who do not consent to the study * permanent or persistent atrial fibrillation * patients who have underwent prior catheter ablation for atrial fibrillation * chads-vasc score more than 2 * history of stroke * lvef \<40% * significant liver or kidney dysfunction * history of major bleeding during warfarin therapy